Modeling human trophoblast-NK cell interactions in term and preterm birth

足月和早产时人类滋养层 - NK 细胞相互作用的建模

基本信息

  • 批准号:
    10770207
  • 负责人:
  • 金额:
    $ 15.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract The human placenta is a semi-allogeneic tissue whose growth and development requires tolerance by the maternal immune system. In fact, the maternal immune system faces a challenge during pregnancy: to maintain tolerance toward foreign fetal alloantigens while simultaneously staging a response to potential pathogens at the maternal-fetal interface. The mechanisms through which placental cells evade maternal immune recognition are poorly understood, particularly in the context of human pregnancy. The uterine lining, called decidua, is a particularly-understudied and important microenvironment, because it is the interface where placental cells called extravillous trophoblast (EVT) come in close contact with maternal immune cells, of which decidual natural killer (dNK) cells are the most abundant. EVT are highly invasive cells which are required for proper remodeling of the maternal uterine lining, including vascular remodeling which leads to establishment of maternal blood flow to the placenta. Interactions between placental EVT and decidual leukocytes are known to facilitate maternal vascular remodeling by EVT and limit the extent of EVT invasion into the uterine wall. Indeed, problems in preterm birth could result from inappropriate responses by dNK cells. Unfortunately, interactions between dNK and trophoblasts are difficult to study in an ongoing pregnancy, due to lack of access to the decidual compartment, where these important interactions occur. While animal models have offered some insights into these processes, they do not accurately model human placentation and pregnancy. The goal of the original R01 proposal is to evaluate the decidual cell population in both term and preterm birth, then to combine this knowledge with the latest technologies in regenerative medicine to develop in vitro models for the study of dNK-EVT interactions. Specifically, we proposed to generate matched maternal and placental induced pluripotent stem cells (iPSC), and differentiate these cells into dNK cells and EVT, respectively, in order to model interactions between these two cell types. Given the known association between male fetal sex and risk of preterm birth, we had focused our efforts on characterizing, banking, and reprogramming cells from mom:male baby pairs in the original application. However, to fully understand mechanisms that predispose to sPTB, it would be best to compare these data to those from mom:female baby pairs. Therefore, we now propose to characterize, bank, and reprogram cells from mom:female placenta pairs for this administrative supplement. Successful completion of this proposal will establish a reproducible and manipulatable model system for studying interactions between the maternal immune system and both the male and female placenta.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jack D Bui其他文献

Jack D Bui的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jack D Bui', 18)}}的其他基金

Optimization of CAR-Bacteria for Oral Cancer
口腔癌 CAR 细菌的优化
  • 批准号:
    10648292
  • 财政年份:
    2023
  • 资助金额:
    $ 15.8万
  • 项目类别:
Modeling human trophoblast-NK cell interactions in term and preterm birth
足月和早产时人类滋养层 - NK 细胞相互作用的建模
  • 批准号:
    10211100
  • 财政年份:
    2021
  • 资助金额:
    $ 15.8万
  • 项目类别:
Modeling human trophoblast-NK cell interactions in term and preterm birth
足月和早产时人类滋养层 - NK 细胞相互作用的建模
  • 批准号:
    10549321
  • 财政年份:
    2021
  • 资助金额:
    $ 15.8万
  • 项目类别:
Modeling human trophoblast-NK cell interactions in term and preterm birth
足月和早产时人类滋养层 - NK 细胞相互作用的建模
  • 批准号:
    10370386
  • 财政年份:
    2021
  • 资助金额:
    $ 15.8万
  • 项目类别:
Innate anti-tumor immune responses
先天性抗肿瘤免疫反应
  • 批准号:
    8894151
  • 财政年份:
    2011
  • 资助金额:
    $ 15.8万
  • 项目类别:
Innate anti-tumor immune responses
先天性抗肿瘤免疫反应
  • 批准号:
    8670837
  • 财政年份:
    2011
  • 资助金额:
    $ 15.8万
  • 项目类别:
Innate anti-tumor immune responses
先天性抗肿瘤免疫反应
  • 批准号:
    8193740
  • 财政年份:
    2011
  • 资助金额:
    $ 15.8万
  • 项目类别:
Innate anti-tumor immune responses
先天性抗肿瘤免疫反应
  • 批准号:
    9052306
  • 财政年份:
    2011
  • 资助金额:
    $ 15.8万
  • 项目类别:
Innate anti-tumor immune responses
先天性抗肿瘤免疫反应
  • 批准号:
    8465750
  • 财政年份:
    2011
  • 资助金额:
    $ 15.8万
  • 项目类别:
Innate anti-tumor immune responses
先天性抗肿瘤免疫反应
  • 批准号:
    8494121
  • 财政年份:
    2011
  • 资助金额:
    $ 15.8万
  • 项目类别:

相似海外基金

Operational tolerance induction by alloantigen-induced Treg cell therapy in rat lung transplantation
同种异体抗原诱导的 Treg 细胞疗法在大鼠肺移植中诱导操作耐受
  • 批准号:
    23K08289
  • 财政年份:
    2023
  • 资助金额:
    $ 15.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10432434
  • 财政年份:
    2022
  • 资助金额:
    $ 15.8万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10744193
  • 财政年份:
    2022
  • 资助金额:
    $ 15.8万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10534556
  • 财政年份:
    2022
  • 资助金额:
    $ 15.8万
  • 项目类别:
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10612453
  • 财政年份:
    2022
  • 资助金额:
    $ 15.8万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10204102
  • 财政年份:
    2019
  • 资助金额:
    $ 15.8万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10443701
  • 财政年份:
    2019
  • 资助金额:
    $ 15.8万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10737340
  • 财政年份:
    2019
  • 资助金额:
    $ 15.8万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10652374
  • 财政年份:
    2019
  • 资助金额:
    $ 15.8万
  • 项目类别:
Generation of alloantigen-specific Designer Platelets for diagnostic and investigative use
生成用于诊断和研究用途的同种异体抗原特异性设计血小板
  • 批准号:
    9005358
  • 财政年份:
    2016
  • 资助金额:
    $ 15.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了